交大昂立(600530) - 2025 Q4 - 年度业绩预告
JIAODA ONLLYJIAODA ONLLY(SH:600530)2026-03-23 10:50

Financial Performance Expectations - The company expects to achieve an operating revenue of approximately CNY 315 million for 2025, with a net profit attributable to shareholders of about CNY 4.5 million, and a non-recurring net profit of approximately -CNY 7 million, representing a year-on-year decrease of about CNY 12.81 million or 220%[2] - The decline in performance is primarily attributed to a decrease in revenue from the health products segment for 2025[2] - The company expects a net profit attributable to shareholders of approximately 4.50 million for 2025, with a non-recurring net profit of approximately -7.00 million[30] - The estimated non-recurring profit and loss for 2025 is approximately 1,150 million[31] Revenue Breakdown by Segment - The health products segment generated revenue of CNY 136.68 million, while the medical and nursing segment contributed CNY 157.84 million, and the real estate segment accounted for CNY 16.81 million, totaling CNY 314.70 million across all segments[6] - The total revenue for the health product segment is CNY 13,667.94 million, with online sales contributing CNY 3,459.95 million and offline sales contributing CNY 10,207.99 million[19] - The real estate segment's total revenue from leasing activities reached CNY 111.44 million, with the largest lease contributing CNY 26.27 million[12] - The company reported a total of CNY 28.00 million in revenue from pawn services in the other segment, with the largest transaction amounting to CNY 4.23 million[14] Customer and Supplier Relationships - The top ten customers in the health products segment accounted for a total sales revenue of CNY 704.02 million, with the largest customer contributing CNY 172.82 million[7] - The total procurement amount from major suppliers in the health product segment is CNY 18,072,295.36, with long-term cooperation established for over 10 years with several suppliers[16] - The total procurement amount from major suppliers in the medical care segment is CNY 29,225,386.59, with ongoing relationships since 2019 for most suppliers[16] - The company confirmed that there are no related party transactions between major customers and suppliers, ensuring compliance with regulations[17] Revenue Recognition and Compliance - The company is required to disclose detailed information regarding revenue recognition, customer transactions, and sales return situations for 2025[2] - The revenue recognition policy adheres to the new revenue standards, with all sales confirmed based on external evidence such as customer acceptance and logistics records[23] - The company has established clear revenue recognition policies for each business segment, ensuring compliance and accuracy in financial reporting[22] - The company’s revenue recognition practices are in line with the five-step model of the new revenue standards, ensuring that all criteria are met before recognizing revenue[22] Financial Management and Liabilities - As of the end of 2025, the company's cash and cash equivalents decreased to 263.12 million yuan from 481.99 million yuan, while total assets decreased to 45.38 million yuan from 53.53 million yuan[34] - The company’s total liabilities decreased to 17.54 million yuan from 29.07 million yuan, with other payables decreasing to 17.47 million yuan from 28.99 million yuan[34] - The company’s total equity increased to 27.84 million yuan from 24.46 million yuan, with retained earnings showing a slight improvement[34] - The company reported a decrease in other receivables by 6.4 million yuan due to the recovery of loans from related parties[35] Audit and Compliance Measures - The total revenue for the auditing firm for 2025 is projected to be 8,829,077.84 yuan, with the audit fee for the company being 1.2 million yuan, representing approximately 13.59% of the firm's total revenue[63] - Shenzhen Zhengyi has implemented specific measures to maintain independence, including prohibiting direct economic relationships with clients outside of professional service fees[66] - The company has established a quality control review system, categorizing the annual report audit as Class A business and implementing a seven-level review process[66] - The audit team will maintain independence and reasonable professional skepticism, adhering strictly to accounting and auditing standards[68] Legal and Litigation Matters - The ongoing litigation involving Angli Small Loan may have uncertain impacts on the company's financial reports, as the outcome is still pending[38] - The company successfully defended against a lawsuit regarding a 40 million yuan fund transfer, with the court ruling in favor of Jiuding Pawn[51] - The debt relationship between Jiuding Pawn and the company was confirmed in 2024, following a court ruling that resolved uncertainties regarding a lawsuit involving a minority shareholder[57] Loan Management and Provisions - Jiuding Pawn's financial management includes a provision policy that mandates a 50%-75% provision for doubtful loans, ensuring prudent risk management[53] - The company reported a total of 5.7 million yuan in loans to Angli Small Loan, with a significant portion classified as impaired[52] - Jiuding Pawn classified the remaining 1.25 million yuan loan from Angli Small Loan as "doubtful" and provisioned for 937.5 thousand yuan, reflecting a 75% impairment rate[53] - The company plans to return 4.5 million yuan to Jiuding Pawn in 2025, which will lead to a reversal of the corresponding impairment provision[59]

JIAODA ONLLY-交大昂立(600530) - 2025 Q4 - 年度业绩预告 - Reportify